A clinical method for estimating the rate of growth of a cancer. by Feinstein, A. R.
Yale University School of Medicinte, 333 Cedar Street,
ALVAN R. FEINSTEIN* Newz Haven, Contnt. 06510 and
Veterans Administrationt Hospital, West Haven, Contnl.
A CLINICAL METHOD FOR ESTIMATING THE RATE OF GROWTH OF A CANCERt
The rate of growth of a human cancer is frequently discussed but seldom
mleasured. The measurement would require the calculation of a proportion,
or rate, in which the numerator represents a chanige of growth, and the
denominator, an interval of time during which the change occurred. The
necessary data for this calculation would be an assessment of the state of
the cancer in its human host at each of two different points in time. The
difference between the two states would be the numerator, and between
the two times, the denominator.
Such measurements are rarely used for appraising rate of growth when
a cancer is discovered in an individual patient. Instead, treatment is usu-
ally planned and reported on the basis of an anatomic staging system that
cites the extensiveness of the tumor at the time of its detection. Although
this citation of anatomic extensiveness is satisfactory for denoting an
amount or direction of growth, it does not account for functional effects
of growth, and it indicates neither a change in growth nor a rate.
One of the main reasons for not measuring these phenomena has beeni
the difficulty of getting evidence that is satisfactory in both time and
content. In time, the usable evidence must be restricted to what was
learned during the temporal interval before the cancer received any treat-
ment that might alter its natural rate of growth. Although the date of
treatment can serve as the endpoint of this interval, no standard concepts
have been established for the time to be cited as an opening date. In con-
tent of evidence, the structural aspects of a cancer's growth can be classified
with the traditional system of anatomic staging, but no systems of classifi-
cation have been available for the clinical manifestations that denote func-
tional effects. And even the structural measurements are necessarily
imprecise, because the exact size of a cancer can be determined only if it
is removed at surgery - a procedure that can be done only once for
most patients, and not at all for many.
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MIy purpose in this paper is to suggest specific points in time that can
be used for these assessments, and to propose a method for estimating
rate of growth of a cancer from conventional clinical evidence that can
denote both the structural and functional effects of growth.
"Datemiiarks" in the natural history of a cancer
After a cancer has been diagnostically identified, the clinician can find
several principal "datemarks" for the cancer's previous course in that
patient. The time sequence of some of these "datemarks" is shown in
Fig. 1, and is discussed in the sections that follow.
Date of oniset; "latest negative"
The date of onset of a cancer can never be determined. Even if a person
has continuous daily medical examinations from birth, the exact moment
at which a cancer begins cannot be distinguished. The clinician would be
unable to decide whether the newly discovered lesion began on the day
it was first noticed, or whether its previous growth had now reached the
point of detectability.
Since a date of onset cannot be determined, the clinician can look for
an alternate date that may often be specifically demarcated: the latest
negative. The latest negative refers to the date of the most recent time
at which negative results were found during an appropriate examination
of the site at which the current cancer is now detected. As shown in
Figure 1, the latest negative examination may have occurred before or
after the onset of the cancer.
For example, in lung cancer, the latest negative date would be the
time of the most recent roentgenogram at which no evidence of the current
tumor was visible; in breast cancer, this date would be the most recent
examination of the breast (by any reliable observer, including the patient)
at which no evidence of the current lump could be palpated.
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FIG. 1. "Datemarks" in the natural history of a cancer.
(For further details, see text.)
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When the date of latest niegative is selected from the available data,
the compared examinations should be commensurate. For example, a
previously normal digital palpation of the rectum should not be regarded
as a negative examination for a cancer that is later visible at sigmoidoscopy
but not palpable digitally. The details of criteria for "commensurate"
examinations are described elsewhere.'
Date of first objective evidence; "earliest positive"
Objective evidence of a cancer's presence can be noted from roentgeno-
grams, from endoscopy, from physical examination, and occasionally, from
a laboratory test.* The earliest positive refers to the first test or examination
at which objective evidence of the current tumor, or of an appropriate
''ancestor," was noted to be present.
Date of first symtptonts; "initial symptomt(s)"
The date of the first symptom(s) attributable to the cancer is determined
after careful history-taking and diagnostic appraisal of each of the patient's
symptoms. This date is easily selected when the patient's symptoms have
had a distinct, abrupt onset and when the patient has no other disease that
may produce the symptoms ordinarily associated with the cancer under
scrutiny. If the symptoms have had an insidious onset, an upper time
limit for them can usually be found by reference to the presence or absence
of the symptoms at notable previous dates in the patient's life. The tech-
niques for performing such assessments have been discussed elsewhere.2
If the patient with cancer has an associated "simulating" disease, the
decision about attribution of symptoms may be difficult. For example,
when hemoptysis occurs in a patient who has chronic bronchitis and lung
cancer, the source of the hemoptysis is uncertain; the attribution of blood
in the stools may be uncertain in a patient with cancer of the rectum
who also has hemorrhoids or diverticulosis.
With astute diagnostic reasoning, many of these difficulties can be
resolved, but many other "attribution" decisions will remain uncertain.
Of the totality of symptoms present in a patient with cancer, some will
be unequivocally attributed to some other disease; some will be unequivoc-
ally attributed to the cancer; and others will be of uncertain attribution,
in that the clinician cannot be sure of whether the symptoms are due to
the cancer, to a co-existing disease, or to both. In selecting the initial
symptomt(s) due to the cancer, the clinician can restrict the list of candi-
dates to those unequivocally attributable to the cancer, or he can also
include the symptoms of uncertain attribution. The decision is often
*For example, an elevated acid phosphatase in cancer of the prostate, or certain
abnormal serum proteins in multiple myeloma.
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simplified when symptoms of "certain" attribution have begun earlier
than, or contemporaneously with, those of "uncertain" attribution.
(The problem is not as difficult as it may seem. In studies of medical
records of patients with lung cancer and rectal cancer,3" this "attribution"
issue was significant in only about 10 percent of cases, and the problem
might have been less frequent if all the patients had been available for
direct interview. Since no major difference in the general statistical
distinctions were found3" when the "uncertain attribution" group of
symptoms was either excluded or included among the candidates for
initial symtptom(s), the simplest general policy is to include such symptoms
among the candidates.)
"Zero time"; the date of therapeutic decision
In addition to the three dates just cited, a fourth "datemark" can be
used as a "zero tite," or index point of temporal reference, for comparing
the biologic behavior and rate of growth of a cancer in different patients.
The disadvantages and advantages of different "datemarks" for zero
time have been discussed elsewhere.12 In a survey of clinical course and
therapy for a large series of cases, the best choice of zero time is the date
of the first anti-neoplastic treatment for the cancer. In a prospective
therapeutic trial, or in the selection of treatment for an individual patient,
the reference date would be the time at which the therapeutic decision
is made. In calculating some of the intervals to be cited later, and in
assessing certain changes in size or functional effects of the cancer, the
term zero state will refer to the patient's condition at zero time.
Anatontic and functional direction of a cancer's growth
The anatomic evidence obtained by physical examination, endoscopy,
radiography, and biopsy enables clinicians to estimate the extent to which
a tumor has physically disseminated in a patient's body. For example,
metastases may be palpable in lymph nodes or liver, observable in roent-
genograms of bones or other regions, or microscopically demonstrable in
sites subjected to biopsy. Such anatomic evidence, however, does not
necessarily indicate that the tumor has affected the function of the involved
site. For example, despite small or large amounts of metastatic cancer, a
liver may continue to function normally; a bone may remain painless and
unbroken; and a brain may show no overt neurologic disturbance.
Not only does anatomic evidence often fail to indicate the clinical
effects of a cancer, but the clinical manifestations of the patient often
denote impairments for which no structural counterparts are possible
or available in the patient's anatomic evidence. Some of the systemic
functional effects - such as weight loss or fatigue - cannot be assessed
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anatonmically. Other functional effects of a cancer can occur systemically,
remote from the primary site, as "endocrinopathies" or "neuropathies"
that cannot be discerned from the conventional procedures used either
to examine the cancer itself or to classify the anatomic "stage."
Other types of clinical effects imply anatomic lesions that may not be
actually demonstrated in a particular patient during life, because the
demonstration is undesirable or hazardous. For example, in a patient
with cancer of the lung, the symptom of hoarseness and the endoscopic
visualization of a non-moving vocal cord imply that the recurrent laryngeal
nerve is involved by a neoplastic mass, but the mass may not be demonstra-
ble by conventional roentgenography; a diagnosis of cerebral metastasis
nmay be made on the basis of clinical and electroencephalographic manifesta-
tions although the ordinary skull roentgenogram shows no abnormalities.
In the situations just cited, surgery or dye-contrast roentgenography might
be therapeutically undesirable and not usable as a means of confirming
the anatomic spread of the cancer. The anatomic inferences made from
the functional clinical evidence in these patients would thus be the only
indication of metastatic anatomic involvement an involvement that is
deduced clinically but not actually demonstrated with any anatomic form
of examination.
Because the acquired items of evidence that indicate neoplastic form
and fiunction are so often "dissociated" in individual patients, the growth
of a cancer cannot be appraised merely from its size or anatomic dis-
semination. The functional effects must also be classified and assessed.
The functional effects of a tumor are reflected in the clinical types of
symptoms and signs that it produces. Each clinical manifestation due to a
cancer can be toponymically categorized as primary, systemic, or meta-
static. Primnary clinical features are attributable to the tumor at its primary
site, or to surrounding inflammation; and no primary feature implies
per se that the tumor has spread beyond the primary site. Examples of
primary symptoms are hoarseness in cancer of the larynx, hemoptysis in
cancer of the lung, and alteration of stools in cancer of the rectum.
Systemtic clinical features arise in the body as a whole or at sites remote
from the primary tumor, but these features also do not per se imply
anatomic dissemination of tumor beyond the primary site. Anorexia, weight
loss, and fatigue are examples of systemic symptoms in the three cancers
just cited. Metastatic clinical manifestations imply physical spread of the
tumor beyond the primary site. Examples of metastatic symptoms in the
three cited cancers are pain due to metastasis in the bony pelvis, and
jaundice due to neoplastic invasion in or near the liver.
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Details of this functional toponymic classification of symptoms in cancer
have been described elsewhere.' For describing the patient's zero state,
these categories of clinical toponymy can be used as indexes (or "stages")
of the functional growth of a tumor, supplementing the structural evidence
used to indicate anatomic growth.'
Time intervals of growth of a cancer
The cited "datemarks" of latest negative, earliest positive, initial symp-
tom(s), and zero time can be used for calculating the intervals shown
in Figure 2. In these calculations, the first manifestations will be either
the earliest positive objective evidence or the initial symptoms, according
to whichever came first.
Inception interval
The inception interval is the time elapsed between the latest negative
and the first manifestations. If a latest negative examination is not available,
this interval cannot be calculated.
Progression interval
The progression interval is the time elapsed between the first ntanifesta-
tions and zero time. This interval can always be calculated, since a patient
who receives the diagnosis of cancer must have either symptoms or some
objective evidence of the cancer.
Deductions about rate ofgrowth
For calculating rate of growth of the cancer found at zero state, the
numerator of the ratio will represent directional changes in anatomic and
functional growth of the tumor; the denominator will represent the time
during which these changes occurred. A cancer is most likely to be bio-
logically "benign" if it has had a favorable direction of growth-i.e., no
anatomic dissemination, and no systemic or metastatic functional effects-
over a long duration of time.
FIG. 2. Time intervals of growth of a cancer.
(For further details, see text.)
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The change in growth, from one state to another, will reflect these
directional aspects of the cancer, while the change in time will reflect
the rapidity of the increment in growth. A cancer that has grown un-
favorably, having already produced metastatic manifestations when it is
detected, can seldom be "cured" no matter how slowly it has grown-
but a long duration of growth may indicate that "palliative" surgery or
other vigorous therapeutic procedures are particularly likely to be effective.
On the other hand, a rapid rate of growth may be a harbinger of poor
prognosis even though the direction of growth appears "favorable."
Since the intervals calculated in the previous section will be the critical
denominators of the growth ratio, these intervals require thoughtful
interpretation.
A long inception interval
A long inception interval has no significance. Since the length of this
interval depends on when the latest negative examination occurred, the
interval can be extremely long merely because the old examination took
place many years previously. For example, in a patient whose earliest
positive chest roentgenogram for lung cancer was noted when he was 58
years old, the only available previous negative film may have been taken
when he was 22.
A short inception interval
A short inception interval generally implies a rapidly-growing tumor.
The shorter the interval, and the greater the change in growth during that
interval, the more likely is the tumor to be rapid-growing. For example,
if a woman's breast showed no lump two months ago and a large lump
now, the lump has grown rapidly. Similarly, in a patient who has chest
roentgenograms taken every six months, a negative film at one examina-
tion followed by a large mass in the film of the next examination would
sug,gest rapid growth. Thus, despite such "early discoveries" of cancer,
the results of treatment may be poor because the cancer is rapid-growing.
a short progression interval
A short progression interval has no significance per se unless a large
amount of change takes place during that interval. For example, the
earliest positive evidence of a cancer in an asymptomatic patient may
have been found only a week before the patient's admission to the hospital
for treatment. In such circumstances, the short progression interval is
attributable to the medical procedures of man, rather than to the biologic
course of nature, and cannot be used to assess the growth of the cancer.
In patients whose initial symptoms were the first manifestations of cancer,
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no definite conclusion can be drawn from a short progression interval,
unless a dramatic increnient of systemic and metastatic symptoms has
accrued during that interval. The interval may have been short because
the tumor grows rapidly, but the brief duration may alternatively repre-
sent the "top of an iceberg" - resulting from a slow-growing tumor that
has finally reached the point of symptomatic eruption.
A long progression interval
A long progression interval implies a slow-growing tumor. The only
way in which a patient could still be alive for a long time after the first
manifestations of the tumor is for the tumor to have grown slowly. With
a long progression interval, the tumor may have grown in an unfavorable
anatomic or functional direction, but its growth has been slow. For this
reason, and because onset of symptoms is often the first manifestation
used for calculating the progression interval, a reasonable aphorism about
the rate of growth of tumors is that slow-growing tumors produce symp-
toms slowly.'
DISCUSSION AND CLINICAL APPLICATIONS
Most existing concepts of rate of growth for human cancers have been
based on data obtained by three techniques, each of which has distinct
disadvantages:
[1]. From observation of cellular types, pathologists have concluded
that "differentiated" cancers tend to grow slowly and "undifferentiated"
ones rapidly. The disadvantage of these histopathologic concepts is that
they represent general conclusions, which might not apply to an individual
patient; moreover, they are based on microscopic appearances, which do
not contain direct appraisals of either growth or time.
[2]. The rate of growth of an excised cancer can be observed when
part of it is grown in an animal or in some other medium outside the
patient's body. This procedure has two disadvantages: a piece of the
cancer cannot always be obtained during the patient's lifetime, and the
extra-corporeal growth deprives the cancer of any constitutional resist-
ance from the human host. Consequently, the results cannot readily be
extrapolated to what happened when the cancer was part of the host.
[3]. A frequently used endo-corporeal approach has been based on
wholly objective evidence, obtained from review of earlier examinations,
via roentgenography, endoscopy, or palpation, of the region in which the
cancer has now been detected. The disadvantage of this approach is that
a preceding examination may not have been done, or may not have been
performed or recorded in a manner suitable for comparison with the
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current state. Moreover, the size of the cancer noted at these examinations
may be difficult to interpret because of associated inflammation or observer
variability.
The technique proposed in this paper is an attempt to improve the endo-
corporeal approach by analyzing the patient's symptoms as well as the more
"objective" clinical and para-clinical evidence. The proposed method of
estimating rate of growth cannot be illustrated with a plethora of support-
ing data, because relatively little appropriate information is available. The
duration and other necessary distinctions of symptoms are often not given
explicit attention in the histories taken from most patients, and previous
objective evidence of a cancer - in either physical, endoscopic or roent-
genographic examinations - is not regularly looked for. Moreover, even
when satisfactory information is obtained about symptomatic distinctions
and previous objective evidence of cancer, the information is seldom
specifically classified and analyzed in large-scale statistical tabulations.
The foregoing discussion has therefore been concentrated on a method-
ologic rationale for future research, since most existing investigations of
cancer have not provided data with which to test the concepts. The re-
maining discussion will be devoted to summarizing the supporting data
contained in the few investigations where these problems have been ex-
plored, and to proposing a way of using these concepts to clarify some
of the confusion that now exists in the study of breast cancer.
A short inception interval
Since roentgenograms of the chest are so easily obtained, cancer of the
lung is one of the few neoplasms for which the inception interval has been
studied systematically enough to warrant formal analysis. In particular,
Weiss, Boucot, and Cooper' have appraised the post-therapeutic survival
after detection of lung cancer during the semi-annual photofluorographic
examinations of more than 6,000 men. The growth rate of the cancer was
determined as a "doubling time" based on the increment of size during the
6-month inception interval from a "negative" to a "positive" radiographic
examination. Smaller tumors had longer doubling times, and such patients
survived generally longer than those with a short doubling time. In such
circumstances, a large increment in growth during a relatively short
inception interval indicated a rapidly-growing tumor.
A long progression interval
That cancers of the lung can often grow slowly - even with anaplastic
cell types - has now been well established from many radiologic studies.s'
What has not been frequently quantified, however, is that survival rates
in lung cancer may be no better in certain patients discovered sympto-
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matically "early" rather than "late." For example, among patients who
had only primary symptoms of lung cancer, the survival rates were actually
somewhat higher in those who had a long rather than short duration of
pre-therapeutic symptoms." In particular, among patients who had no
pre-operative anatomic evidence of dissemination beyond the primary site,
the 5-year survival rate after resection of the cancer was 34 percent
[10/29] in those with a long duration of only primary symptoms, and
21 percent [5/24] in those with a short duration."0
In a similar study of the symptomatic progression interval in patients
with rectal cancer who had no evidence of anatomic dissemination of
cancer beyond the primary site, the 5-year survival rate after surgical
resection was 67 percent [29/43] in the group with "long primary"
symptoms, and 54 percent [18/33] in the "short primary" group.' The
importance of a long progression interval has also been noted in several
cancers other than pulmonary or rectal neoplasms. In Hodgkin's disease,
and in cancer of the stomach, recent investigators have reported the
apparent paradox of good survival in patients with long "delays" before
treatment.
Although such long survivals, despite "delays" in treatment, have often
been noted in patients with cancer, the phenomenon has usually been
considered a caprice of nature or an idiosyncrasy of the human psyche,
rather than a clue to the biologic behavior of cancer."4 Slow-growing,
favorably-directed tumors can regularly be expected to have a long pro-
gression interval; and protracted primary symptoms, without the develop-
ment of systemic or metastatic symptoms, can be used predictively as an
index of relatively good prognosis.
Cancer of the breast
Despite volumes of statistics based on anatomic staging of breast cancer,
the treatment of this disease is perhaps more controversial today than
that of any other human neoplasm. One possible reason for the controversy
is that the morphologic classifications, which depend on size, fixation,
localization, and cellular type, make no provision for the rate of growth
of the cancer. Consequently, slow-growing and rapid-growing tumors may
be admixed in the same morphologic category, leading to undetected and
unresolved discrepancies in the post-therapeutic data.
Since cancer of the breast seldom produces symptoms, its rate of growth
must be assessed from physical signs of the length of time that the tumor
was, or might have been, present before it was detected in its "zero
state." A progression interval can always be calculated for the time elapsed
between the patient's notation of the current lump and zero time. An
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additional question should always be asked, however, of any patient with
cancer of the breast. The question is: "When was your breast examined
in the past, before this current lump was noted, and what was found?"
After this question is answered, and after any previous examiners are
consulted, the data may be arranged in three possible categories.
[1] No previous examination was done, or the results of previous
examinations are unknown. In this case, no inception interval can be
calculated. The clinician has no idea of how long the tumor might have
been present before its recent discovery.
[2] A previous examination was performed, with negative findings. In
this case, an inception interval can be calculated, and, if short, will imply
a rapid-growing tumor.
[3] A previous examination was done, and showed the same lump as
now, present in some ancestral form. Further questions should then be
asked to elicit information about a latest negative examination of the
breast. Regardless of the answer to the additional questions, this patient's
progression interval can be calculated, and, if long, will imply a slow-
growing tumor.
\\Tith this information, a breast cancer can be classified as slow-growing
(long progression interval), rapid-growing (short inception interval),
or of uncertain rate of growth (inception interval unknown or long, and
progression interval not long). If patients with comparable "anatomic
stages" were further subclassified according to these "clinical" or "bio-
logic" stages, the results of different modes of therapy might be more
effectively analyzed, because the comparisons would contain groups that
are biologically more homogeneous and clinically more comparable.
SUNIMARY
The rate of growth of a cancer in its human host is not assessed
effectively from histopathologic inferences, anatomic "stages," or attempts
to grow the cancer outside the host's body.
In measuring rate of growth, the numerator of the ratio (changes in
growth) should deal with functional as well as structural effects of the
cancer. The denominator (time of growth) must deal with measured
intervals of time. Structural evidence of cancer, obtained during appropriate
previous examinations, can provide some of the information needed for
this calculation, but such previous examinations have not always been
performed in all patients, and the data, even when available, are not
always satisfactory for the necessary decisions. An alternative source of
useful information is an account of the clinical manifestations of the
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patient. These data help denote both the functional direction and duration
of a growing cancer.
From the classified clinical symptoms and other evidence of cancer,
two important intervals can be calculated: an inception interval, from the
date of the latest negative examination to the first symptomatic or other
manifestations of the cancer; and a progression interval, from the first
manifestations of the cancer to the time of the first therapeutic decision.
In general. a short inception interval implies a rapid-growing tumor,
and a long progression interval implies a slow-growing tumor.
Further aspects of these principles are discussed, and an application
is suggested to improve the analysis of data for cancer of the breast.
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